For some of the leading drugmakers, currently, the first priority is to find an effective treatment for Covid-19, which was declared a
Fresh hope for Covid-19 patients as AbbVie (ABBV) leads studies on HIV drug
Categories
Biotechnology
Dynavax Technologies Corporation (NASDAQ: DVAX): Q4 2019 Earnings Snapshot
-- Biopharmaceutical company Dynavax Technologies Corporation (NASDAQ: DVAX) reported a net loss of $36.8 million $0.44 per share for the fourth quarter
Novavax (NVAX) posts wider-than-expected loss in Q4
Novavax Inc. (NASDAQ: NVAX) reported a narrower loss for the fourth quarter of 2019 helped by higher revenue and lower expenses. The
Avid Bioservices (CDMO) Q3 2020 Earnings Snapshot
-- Avid Bioservices (NASDAQ: CDMO) reported a loss of $0.## per share for its third quarter of 2020 vs. expected loss of
Catabasis Pharmaceuticals (NASDAQ: CATB): Q4 2019 Earnings Snapshot
-- Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) reported a net loss of $6.6 million or $0.55 per share for the fourth quarter of
Akebia Therapeutics (AKBA) Q4 2019 Earnings Snapshot
-- Akebia Therapeutics (NASDAQ: AKBA) reported fourth quarter 2019 loss of $0.79 per share vs. expected loss of $0.47 per share. --
Minerva Neurosciences (NASDAQ: NERV): Q4 2019 Earnings Snapshot
-- Minerva Neurosciences Inc. (NASDAQ: NERV) reported a fourth-quarter 2019 loss of $29.9 million or $0.77 per share, wider than a loss
BioXcel Therapeutics (BTAI) Q4 loss widens on higher expenses
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) reported a wider net loss for the fourth quarter, owing to an increase in research and development
Bio-Path Holdings (NASDAQ: BPTH): 2019 Earnings Snapshot
-- Bio-Path Holdings Inc. (NASDAQ: BPTH) reported a loss of $3.24 share for the full year 2019, narrower than a loss of
Aurinia Pharmaceuticals (NASDAQ: AUPH): Q4 2019 Earnings Snapshot
-- Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a fourth-quarter 2019 loss of $0.78 per share versus a loss of $0.14 per share expected.
Amicus Therapeutics (FOLD): FY 2019 Earnings Snapshot
-- Biotechnology company Amicus Therapeutics (NASDAQ: FOLD) reported a net loss of $356.4 million or $1.48 per share for fiscal 2019, compared
Sage Therapeutics (SAGE) Q4 2019 Earnings Snapshot
-- Sage Therapeutics (NASDAQ: SAGE) reported fourth quarter 2019 loss of $3.25 per share vs. expected loss per share of $3.61. --
ACADIA Pharmaceuticals (ACAD): Q4 2019 Earnings Snapshot
-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q4 2019 loss of $0.34 per share, vs. $0.36 expected. -- Revenue grew 65% to
Sarepta Therapeutics (SRPT): Q4 2019 Earnings Snapshot
-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) reported a loss of $1.57 per share in the fourth quarter of 2019, vs $1.86 per share loss expected.
Moderna (MRNA) ships coronavirus vaccine candidate for trials, shares hit a peak
Shares of Moderna Inc. (NASDAQ: MRNA) soared to a record high of $29.98 on Wednesday after shipping the first coronavirus vaccine candidate
Amarin Corporation (AMRN): Q4 2019 Earnings Snapshot
— Amarin Corporation plc (NASDAQ: AMRN) reported earnings of $0.04 per share in the fourth-quarter 2019 vs. $0.02 per share loss expected. — Revenue grew
MannKind Corporation (MNKD): Q4 2019 Earnings Snapshot
-- MannKind Corporation (NASDAQ: MNKD) reported Q4 2019 loss of $0.07 per share, vs. a loss of $0.07 expected. -- Total revenue
Intercept Pharmaceuticals (NASDAQ: ICPT): Q4 2019 Earnings Snapshot
-- Intercept Pharmaceuticals (NASDAQ: ICPT) reported a fourth-quarter 2019 loss of $2.99 per share versus a loss of $2.67 per share expected.
Clovis Oncology (NASDAQ: CLVS): Q4 2019 Earnings Snapshot
-- Clovis Oncology (NASDAQ: CLVS) reported a fourth-quarter 2019 loss of $1.81 per share versus a loss of $1.71 per share expected.
Excitement continues for BioXcel Therapeutics (BTAI) investors
Once again, the shares of BioXcel Therapeutics (NASDAQ: BTAI) surpassed its previous 52-week high today and closed at $39.59, up 7.09%. BTAI
Medtronic (MDT) beats Q3 earnings estimates; revenues miss mark
Medtronic plc (NYSE: MDT) topped earnings expectations for the third quarter of 2020 while revenue fell short of estimates. The stock was